Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2021 16:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of...
January 05, 2021 08:30 ET | Source: Albireo Pharma, Inc.

Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper,...
December 17, 2020 08:00 ET | Source: Albireo Pharma, Inc.

Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome

- Study represents Albireo’s third global, Phase 3 trial in rare cholestatic liver diseases - - ASSERT gold standard study design in Alagille syndrome - - Product submission of...
December 11, 2020 16:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the...
December 08, 2020 16:30 ET | Source: Albireo Pharma, Inc.

Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC

- Data on PFIC types 1, 2, 3 submitted to support use across a wide range of patients - - EMA grants accelerated assessment, validates Marketing Authorization Application for odevixibat with orphan...
November 13, 2020 08:05 ET | Source: Albireo Pharma, Inc.

New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease

- PEDFIC 1 meets both U.S. and EU primary and secondary endpoints with highly statistically significant reductions in serum bile acids and pruritus - - Interim results from long-term extension...
November 12, 2020 08:00 ET | Source: Albireo Pharma, Inc.

Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences

BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper,...
November 05, 2020 07:30 ET | Source: Albireo Pharma, Inc.

Albireo Reports Q3 2020 Financial Results and Provides Business Update

- Positive Phase 3 data for odevixibat in PFIC with filings on track for no later than early 2021 - - Phase 3 PFIC data accepted as late breakers at upcoming AASLD Meeting - - Introduces new and...
November 02, 2020 08:00 ET | Source: Albireo Pharma, Inc.

Albireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers

- Final PEDFIC 1 and interim PEDFIC 2 results accepted at AASLD’s The Liver Meeting 2020 - - PEDFIC 1 and PEDFIC 2: largest global Phase 3 in children with PFIC types 1, 2 & 3 - - Two abstracts...
October 23, 2020 09:20 ET | Source: Albireo Pharma, Inc.

Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting

-Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases- -Scientific leadership demonstrates company’s commitment to increase understanding...